Editor's Choice
CRISPRing the microbiome is just around the corner
To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]
Editor’s Choice
Biotech Showcase
Bringing the Transformative Power of Synthetic Biology to Medicine
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
Editor's Choice
Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome
Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]
Editor's Choice
Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development
Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]
Editor's Choice
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]
Biotech Showcase
Engineering the Microbiome to Treat Skin Diseases
The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]
Editor's Choice
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The […]
Editor's Choice
Microbes turn back the clock as research discovers their potential to reverse aging in the brain
Research from APC Microbiome Ireland (APC) at University College Cork (UCC) published in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function […]
Editor's Choice
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]
Editor's Choice
Ferring and Rebiotix Present Landmark Phase 3 Data
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]
Editor's Choice
The surprising evolutionary history of our oral bacteria
Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species – our microbiome. These microbes play key roles in human health, but little is known about their evolution. […]